Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04LIH
|
|||
| Former ID |
DIB013093
|
|||
| Drug Name |
AVI-6002
|
|||
| Synonyms |
NeuGene Plus (Ebola virus), AVI; Neugene (Ebola virus), AVI BioPharma; Polymerase cofactor VP35 modulator (Ebola virus infection,TSO), AVI BioPharma; Viral membrane associated protein VP24 modulator (Ebola virus infection, TSO), AVI BioPharma; AVI-4537 + AVI-4538 + AVI-4539 (Ebola virus infection), AVI BioPharma
Click to Show/Hide
|
|||
| Indication | Ebola virus infection [ICD-11: 1D60.0] | Phase 1 | [1] | |
| Company |
AVI BioPharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ebola virus VP24 messenger RNA (EV VP24 mRNA) | Target Info | Modulator | [2] |
| Ebola virus VP35 messenger RNA (EV VP35 mRNA) | Target Info | Modulator | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01353027) Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus. U.S. National Institutes of Health. | |||
| REF 2 | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.